Losartan potassium, which is an ingredient of this drug, is metabolized into carboxylate form, which is an active metabolite, mainly by the drug-metabolizing enzyme cytochrome P450 2C9 (CYP2C9).
Clinical trial data has shown that dual blockade of the RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypertension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent.
Hydrochlorothiazide, which is an ingredient of this drug, is excreted in urine with almost no metabolization. (See Table 4.)
Click on icon to see table/diagram/image